AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02868177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each randomized subject will consume 8 capsules daily of placebo (5064 mg of maltodextrine) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
Study NCT03990857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive care protocol in new diagnosis of Type 2 Diabetes Mellitus and associated comorbidities in Primary Care
Description: This comprehensive intervention is developed in a structured way in the Primary care nurse office. 5 individual intensive visits will be carried out with a weekly or bi-weekly frequency (according to the learning process) to work for an integral care and to transmit the knowledge and skills required. The maximum time expected to receive this 5 visits is 3 months. At least one of the visits, preferably the one that deals with dietary aspects, the patient is asked to be visited with the partner, child or cohabiting person. The research team elaborated the support material with the minimum contents that every patient that begins with T2DM and other chronic pathologies should know. It allows incorporating cultural and emotional aspects. It was agreed with hospital diabetes educators and family doctors. A graphic designer gave an enticing design. A group of patients verified their utility and intelligibility. It is delivered to the person and discussed during the intensification.
Study NCT01233453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the everolimus eluting ® stent
Description: stenting in coronary artery disease using the XIENCE-V®, XIENCE-Prime® or PROMUS® stent
Study NCT01233453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the Biolimus A9 eluting NOBORI® stent
Description: stenting in coronary artery disease using the Biolimus A9 eluting NOBORI® stent
Study NCT02920086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education Program
Description: * The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICS) intervention~* Nutritional education will be provided to ICU patents' families by a dietitian~* Tracking of nutritional information by family~* Encouragement for families to advocate for two or more Oral Nutritional Supplements per day for the patients (approximately 400 kcal/day)
Study NCT02920086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Support Program
Description: * Families will be provided with a web-based decision support tool (My ICU Guide)~* Families will meet with the ICU medical team early in ICU stay to review goals of care
Study NCT03085758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adrecizumab
Description: Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)
Study NCT03085758 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single i.v. dose of placebo (control group)
Study NCT00324129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 given orally three times per week.
Study NCT02420132 — intervention group
Intervention type: OTHER
Intervention: Ranibizumab
Description: Ranibizumab administered as part of standard-of-care
Study NCT01386658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icatibant
Description: Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
Study NCT00119041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Diabetes Treatment Satisfaction Questionnaire
Description: A six question likert scale questionnaire regarding the patients treatment satisfaction. The responses range from very dissatisfied to very satisfied.
Study NCT00119041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Empowerment Scale
Description: A twenty-eight question likert scale questionnaire regarding the patients attitude towards diabetes. The responses range from strongly agree to strongly disagree.
Study NCT00119041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBOC's undergo half-day joint-clinics via teleconference
Description: A patient has Diabetes/Endo clinic visit via teleconferencing. A patient is at a CBOC and the Diabetes/Endo physician is at Wade Park.
Study NCT02950402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two Dried Plums per day
Description: Subjects will consume Two Dried Plums per day
Study NCT02950402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six Dried Plums per day
Description: Subjects will consume Six Dried Plums per day
Study NCT01448122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Avene Compact Honey SPF 50
Description: Patients will have part of their back covered with 2 mg/mL of Avene Compact Honey SPF 50.
Study NCT02610153 — intervention group
Intervention type: DRUG
Intervention: Vitamin K Antagonist
Description: The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
Study NCT01765868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: Single Oral dose 80 mg betrixaban and Single IV (15 ml) carbon 14 80 micrograms Betrixaban administered over 15 minutes, 2 hours after the oral dose
Study NCT02423018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin
Description: In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
Study NCT02423018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
Study NCT02423018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
Study NCT02423018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
Study NCT00288795 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Massage Therapy
Description: Therapeutic Touch
Study NCT00288795 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Polarity Therapy
Description: Use of energy fields to alleviate distress and achieve balance in the body
Study NCT04154332 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Description: Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.
Study NCT02643160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Trunk Training
Description: The intervention includes neurodevelopment treatment, muscle strengthening and functional activities of trunk region
Study NCT00393328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + Ritonavir
Description: Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.
Study NCT00393328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + Ritonavir
Description: Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.
Study NCT05975801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Cupping Therapy
Study NCT05975801 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conservative Treatment (hotpack, transcutaneous electrical nerve stimulation(TENS), ultrasound
Study NCT05975801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment (hotpack, transcutaneous electrical nerve stimulation(TENS), ultrasound
Study NCT03778814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-T cells
Description: Engineering TCR-T cells targeting lung tumor and other solid tumor will be transfused back the patients.
Study NCT02455934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-allulose
Description: Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or >5 days and \<12 days apart.
Study NCT02455934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: D-allulose
Description: Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or >5 days and \<12 days apart.
Study NCT03054207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 300Mg Tablet
Study NCT03054207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300Mg Tablet
Study NCT03054207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 60Mg
Study NCT03054207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 60Mg
Study NCT03096925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-help
Description: Web-based guided self-help intervention
Study NCT03374085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: CC-92480
Study NCT03374085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone
Study NCT03388255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotides
Description: Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~* Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~* Follow up period: 3 months after end of active treatment, without study medication.
Study NCT01678235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Study NCT01678235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Study NCT01684761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tcelna
Description: Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis. Attenuated by irradiation to prevent further proliferation before releasing product for administration.
Study NCT01684761 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.
Study NCT01524055 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Single-Balloon-Enteroscopy with Air as insufflation gas.
Description: Single-Balloon-Enteroscopy will be performed using Air as insufflation gas to inflate the intestine for complete examination.
Study NCT01524055 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Single-Balloon-Enteroscopy with CO2 as insufflation gas.
Description: Single-Balloon-Enteroscopy will be performed using CO2 as insufflation gas to inflate the intestine for complete examination.
Study NCT03271658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web based life support patient decision aid
Description: The web-based life support decision aid (eLSDA) was adapted from a print-based decision aid. The eLSDA includes information on the pros and cons of both life support and comfort care. The eLSDA lays out the decision about life support for an individual patient/family in a logical stepwise fashion to permit discussion, ask questions, and permit reflection on each step. At the end of the eLSDA, unmet decision-making needs are identified to seek support from the healthcare team.
Study NCT03271658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision coaching
Description: During the interactive process of using the eLSDA, the study nurse provides decision coaching for patient/family, specifically a facilitated values clarification exercise.
Study NCT02792179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]RO6958948
Description: Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of \[18F\]RO6958948 injected will be less than or equal to (\</=) 10 micrograms (µg), injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie \[mCi\]).
Study NCT03574441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tegaderm dressing + catheter support pad
Description: Tegaderm TM is a transparent tape. This intervention adds a support pad that comes in the epidural kit to help secure the catheter
Study NCT03574441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm dressing + Steri-strip dressing
Description: Tegaderm TM is a transparent tape. This intervention adds Steri Strips TM of tape to help secure the catheter
Study NCT03574441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm dressing only
Description: Tegaderm TM is a transparent tape. This intervention uses only Tegaderm to secure the catheter
Study NCT04259294 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caspar Telerehabilitation
Description: The experimental group will receive home-based treatment program through mobile apps while control group will receive through a written home program sheets. The training contents will be equivalent, including trunk and lower limb strengthening and stretching, coordination, balance, and functional exercises that will be related to patients' daily living activities in their home.~The frequency and duration of the home program will be compromised by both the therapist and the patient. The videos of the home program will be sent to patients' app in smartphone by the therapist in the experimental group. Patients will perform the exercises while watching the videos in the app. After each exercise will be done, patient's performance feedback will be captured by the smartphone and will be sent back to the case therapist each time through the app while those in the control group will record their performance in a log sheet given by the therapists.
Study NCT04259294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caspar Telerehabilitation
Description: The experimental group will receive home-based treatment program through mobile apps while control group will receive through a written home program sheets. The training contents will be equivalent, including trunk and lower limb strengthening and stretching, coordination, balance, and functional exercises that will be related to patients' daily living activities in their home.~The frequency and duration of the home program will be compromised by both the therapist and the patient. The videos of the home program will be sent to patients' app in smartphone by the therapist in the experimental group. Patients will perform the exercises while watching the videos in the app. After each exercise will be done, patient's performance feedback will be captured by the smartphone and will be sent back to the case therapist each time through the app while those in the control group will record their performance in a log sheet given by the therapists.
Study NCT00752687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABT-072
Description: Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
Study NCT00752687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
Study NCT00146757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 100 U/kg every week
Study NCT00146757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 200 U/kg every week (Week 26 onwards)
Study NCT04585646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orion daily disposable contact lens
Description: Subjects will be randomized to wear Orion lens for 2 weeks.
Study NCT04585646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gemini daily disposable contact lens
Description: Subjects will be randomized to wear Gemini lens for 2 weeks.
Study NCT01248702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of the ICD Critical Pathway
Description: The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
Study NCT03198598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Description: The patients are going to practice Yoga two times per week during 60 minutes each composed by: 40 minutes of postures, 10 minutes of breathing exercises and 10 minutes of meditation. The proposed Yoga postures will depend on disease severity and will be adapted according to each patient.
Study NCT03198598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga app
Description: The patients showing EDSS scores above 6.0 will be divided in two groups of 20. Due to their movements limitations it is not possible to perform a regular Yoga class. In this case they will receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips.
Study NCT05532436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Exercise
Description: It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
Study NCT04227951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avoid drain placement
Description: In No Drain arm (experimental) no abdominal drain is placed at the end of the operation.
Study NCT04227951 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Drain placement
Description: In Drain arm (sham comparator) an abdominal drain is inserted in the abdomen from the right flank, passing below the liver (close to the duodenal stump) with the apex behind the esophago-jejunal (in total gastrectomy) or gastro-jejunal (in subtotal gastrectomy) anastomosis.
Study NCT04095078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMEOX
Description: Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
Study NCT04706754 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Prospectively enrolled participants will be provided with survey packets comprised of different questionnaires at the initial/baseline visit and every 3 months and/or whenever there is an update in their treatment protocol
Study NCT00463268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate
Description: alendronate 70 mg every 2 weeks
Study NCT00463268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium/Vitamin D
Description: Calcium 500 mg and vitamin D supplementation according to serum level
Study NCT00463268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium/Vitamin D
Description: Calcium 500 mg and vitamin D supplementation according to serum level